The State of Black Participation in Clinical Trials

White Paper

The State of Black Participation in Clinical Trials

By Medidata

The State of Black Participation in Clinical Trials

By Medidata

Enter your details to receive the free white paper:

By downloading this whitepaper, you acknowledge that Progressive Media Investments may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how Progressive Media Investments may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Improving diversity in clinical trials is not just the right thing to do, it is necessary for better science, more representative outcomes, and increased health equity. Historically, clinical trials have been shown to recruit disproportionately large percentages of White participants. These skewed participant populations raise concerns about the generalizability of trial results to underrepresented non-White participants and inequitable access to clinical trial treatments. The FDA published updated guidance to address these concerns in April 2022, stating that clinical trial participants need to reflect the demographic distribution of the United States (US) population.

Download to find out more.

The State of Black Participation in Clinical Trials

The State of Black Participation in Clinical Trials

Changelog